CoChat
Sign Up
Cited by 50Chromatin Remodeling and CancerHepatocellular Carcinoma Treatment and PrognosisGenomics and Chromatin Dynamics

Chromatin remodeling gene ARID2 targets cyclin D1 and cyclin E1 to suppress hepatoma cell progression

Open access
Duan, Yujie, Tian, Ling, Gao, Qingzhu, Liang, Li, Zhang, Wenlu, Yang, Yi, Zheng, Yaqiu, Pan, E +2 more·2016·Oncotarget
DOI 10.18632/oncotarget.10244PMC PMC5216766
Open this paper in CoChat — free accountOpen PDF

Abstract

// Yujie Duan 1, * , Ling Tian 1, * , Qingzhu Gao 1, * , Li Liang 1 , Wenlu Zhang 1 , Yi Yang 1 , Yaqiu Zheng 1 , E Pan 1 , Shengwei Li 1 , Ni Tang 1 1 Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, PR China * These authors contributed equally to this work Correspondence to: Shengwei Li, email: lishengwei11@163.com Ni Tang, email: nitang@cqmu.edu.cn Keywords: ARID2, SWI/SNF complex, the Rb/E2F pathway, hepatocellular carcinoma, cell-cycle arrest Received: March 02, 2016 Accepted: June 03, 2016 Published: June 23, 2016 ABSTRACT Exome and whole-genome sequencing studies have drawn attention to the role of somatic mutations in SWI/SNF chromatin remodeling complexes in the carcinogenesis of hepatocellular carcinoma (HCC). Here, we explored the molecular mechanisms underlying the biological roles of AT-rich interactive domain 2 (ARID2) in the pathogenesis of HCC. We found that ARID2 expression was significantly downregulated in HCC tissues compared with non-tumorous tissues. Restoration of ARID2 expression in hepatoma cells was sufficient to suppress cell proliferation and tumor growth in mice, whereas ARID2 knockdown contributed to the enhancement of cellular proliferation and tumorigenicity. Suppression of ARID2 expression accelerated G1/S transition associated with upregulation of cyclin D1, cyclin E1, CDK4, and phosphorylation of the retinoblastoma protein (Rb). Furthermore, we demonstrated that ARID2 physically interacts with E2F1 and decreases binding of E2F1/RNA Pol II to the promoters of CCND1 and CCNE1 . Taken together, these results demonstrate that ARID2 suppresses tumor cell growth through repression of cyclin D1 and cyclin E1 expression, thereby retarding cell cycle progression and cell proliferation in hepatoma cells. These findings highlight the potential role of ARID2 as a tumor growth suppressor in HCC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.10244

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ARID2 is a tumor suppressor and a component of the PBAF complex within the SWI/SNF family of ATP-dependent chromatin remodeling genes.

    “ARID2, a tumor suppressor, is a component of the PBAF complex within the SWI/SNF family of adenosine triphosphate–dependent chromatin remodeling genes (27).”

    From The origin of hepatocellular carcinoma depends on metabolic zonation (2026) · cites this paper as [27]

    The Introduction identifies ARID2 as a tumor-suppressor component of the SWI/SNF complexes and says those complexes mediate ATP-dependent chromatin remodeling. Our copy does not identify ARID2 specifically as a component of the PBAF complex (searched: PBAF), so that part of the claim is unsupported. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 31

  1. [1]Hohmann AF Vakoc CR A rationale to target the SWI/SNF complex for cancer therapy Trends Genet 2014 30 356 363 24932742 PMC4112150
  2. [2]Zhao H Wang J Han Y Huang Z Ying J Bi X Zhao J Fang Y Zhou H Zhou J Li Z Zhang Y Yang X ARID2: a new tumor suppressor gene in hepatocellular carcinoma Oncotarget 2011 2 886 891 10.18632/oncotarget.355 22095441 PMC3259997 · DOI
  3. [3]Wu RC Wang TL Shih IeM The emerging roles of ARID1A in tumor suppression Cancer Biol Ther 2014 15 655 664 24618703 PMC4049780
  4. [4]Yaniv M Chromatin remodeling: from transcription to cancer Cancer Genet 2014 207 352 357 24825771
  5. [5]Mohrmann L Langenberg K Krijgsveld J Kal AJ Heck AJ Verrijzer CP Differential targeting of two distinct SWI/SNF-related Drosophila chromatin-remodeling complexes Mol Cell Biol 2004 24 3077 3088 15060132 PMC381637
  6. [6]Nagl NG Jr Patsialou A Haines DS Dallas PB Beck GR Jr Moran E The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest Cancer Res 2005 65 9236 9244 16230384
  7. [7]Rao Q Xia QY Shen Q Shi SS Tu P Shi QL Zhou XJ Coexistent loss of INI1 and BRG1 expression in a rhabdoid renal cell carcinoma (RCC): implications for a possible role of SWI/SNF complex in the pathogenesis of RCC Int J Clin Exp Pathol 2014 7 1782 1787 24817979 PMC4014263
  8. [8]Dykhuizen EC Hargreaves DC Miller EL Cui K Korshunov A Kool M Pfister S Cho YJ Zhao K Crabtree GR BAF complexes facilitate decatenation of DNA by topoisomerase IIα Nature 2013 497 624 627 23698369 PMC3668793
  9. [9]Watanabe R Ui A Kanno S Ogiwara H Nagase T Kohno T Yasui A SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability Cancer Res 2014 74 2465 2475 24788099
  10. [10]Bitler BG Aird KM Garipov A Li H Amatangelo M Kossenkov AV Schultz DC Liu Q Shih IeM Conejo-Garcia JR Speicher DW Zhang R Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers Nat Med 2015 21 231 238 25686104 PMC4352133
  11. [11]Huang J Deng Q Wang Q Li KY Dai JH Li N Zhu ZD Zhou B Liu XY Liu RF Fei QL Chen H Cai B Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma Nat Genet 2012 44 1117 1121 22922871
  12. [12]Li M Zhao H Zhang X Wood LD Anders RA Choti MA Pawlik TM Daniel HD Kannangai R Offerhaus GJ Velculescu VE Wang L Zhou S Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma Nat Genet 2011 43 828 829 21822264 PMC3163746
  13. [14]Manceau G Letouzé E Guichard C Didelot A Cazes A Corté H Fabre E Pallier K Imbeaud S Le Pimpec-Barthes F Zucman-Rossi J Laurent-Puig P Blons H Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma Int J Cancer 2013 132 2217 2221 23047306
  14. [15]Cajuso T Hänninen UA Kondelin J Gylfe AE Tanskanen T Katainen R Pitkänen E Ristolainen H Kaasinen E Taipale M Taipale J Böhm J Renkonen-Sinisalo L Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer Int J Cancer 2014 135 611 623 24382590
  15. [16]Schulze K Imbeaud S Letouzé E Alexandrov LB Calderaro J Rebouissou S Couchy G Meiller C Shinde J Soysouvanh F Calatayud AL Pinyol R Pelletier L Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets Nat Genet 2015 47 505 511 25822088 PMC4587544
  16. [17]Zhong R Liu L Tian Y Wang Y Tian J Zhu BB Chen W Qian JM Zou L Xiao M Shen N Yang H Lou J Genetic variants in SWI/SNF complexes influences hepatocellular carcinoma risk: a new clue for the contribution of chromatin remodeling in carcinogenesis Sci Rep 2014 4 4147 24556940 PMC3930892
  17. [18]Nagl NG Jr Wang X Patsialou A Van Scoy M Moran E Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control EMBO J 2007 26 752 763 17255939 PMC1794396
  18. [19]Squillaro T Severino V Alessio N Farina A Di Bernardo G Cipollaro M Peluso G Chambery A Galderisi U De-regulated expression of the BRG1 chromatin remodeling factor in bone marrow mesenchymal stromal cells induces senescence associated with the silencing of NANOG and changes in the levels of chromatin proteins Cell Cycle 2015 14 1315 1326 25724006 PMC4614278
  19. [20]Subtil-Rodríguez A Vázquez-Chávez E Ceballos-Chávez M Rodríguez-Paredes M Martín-Subero JI Esteller M Reyes JC The chromatin remodeller CHD8 is required for E2F-dependent transcription activation of S-phase genes Nucleic Acids Res 2014 42 2185 2196 24265227 PMC3936757
  20. [22]Trojer P Li G Sims RJ Vaquero A Kalakonda N Boccuni P Lee D Erdjument-Bromage H Tempst P Nimer SD Wang YH Reinberg D L3MBTL1, a histone-methylation-dependent chromatin lock Cell 2007 129 915 928 17540172
  21. [23]Leung JY Nevins JR E2F6 associates with BRG1 in transcriptional regulation PLoS One 2012 7 e47967 23082233 PMC3474740
  22. [24]Zhu W Giangrande PH Nevins JR E2Fs link the control of G1/S and G2/M transcription EMBO J 2004 23 4615 4626 15510213 PMC533046
  23. [25]Yan HB Wang XF Zhang Q Tang ZQ Jiang YH Fan HZ Sun YH Yang PY Liu F Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription Carcinogenesis 2014 35 867 876 24293408
  24. [26]He F Li J Xu J Zhang S Xu Y Zhao W Yin Z Wang X Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma J Exp Clin Cancer Res 2015 34 47 25975202 PMC4440314
  25. [27]Strobeck MW1 DeCristofaro MF Banine F Weissman BE Sherman LS Knudsen ES The BRG-1 subunit of the SWI/SNF complex regulates CD44 expression J Biol Chem 2001 276 9273 9278 11108719
  26. [28]Reisman DN Strobeck MW Betz BL Sciariotta J Funkhouser W Jr Murchardt C Yaniv M Sherman LS Knudsen ES Weissman BE Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression Oncogene 2002 21 1196 1207 11850839
  27. [29]Luo MX Wong SH Chan MT Yu L Yu SS Wu F Xiao Z Wang X Zhang L Cheng AS Ng SS Chan FK Cho CH Autophagy Mediates HBx-Induced Nuclear Factor- κB Activation and Release of IL-6, IL-8, and CXCL2 in Hepatocytes J Cell Physiol 2015 230 2382 2389 25708728
  28. [30]Nie D Shan X Nie L Duan Y Chen Z Yang Y Li Z Tian L Gao Q Shan Y Tang N Hepatitis C virus core protein interacts with Snail and histone deacetylases to promote the metastasis of hepatocellular carcinoma Oncogene 2015 11 9 10.1038/onc.2015.428 [Epub ahead of print] 26549030 · DOI
  29. [31]Xie Q Chen L Shan X Shan X Tang J Zhou F Chen Q Quan H Nie D Zhang W Huang AL Tang N Epigenetic silencing of SFRP1 and SFRP5 by hepatitis B virus X protein enhances hepatoma cell tumorigenicity through Wnt signaling pathway Int J Cancer 2014 135 635 646 24374650
  30. [32]Liu J Ding X Tang J Cao Y Hu P Zhou F Shan X Cai X Chen Q Ling N Zhang B Bi Y Chen K Enhancement of canonical Wnt/β-catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells PLoS One 2011 6 e27496 22110662 PMC3216985
  31. [33]Quan H Zhou F Nie D Chen Q Cai X Shan X Zhou Z Chen K Huang A Li S Tang N Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition Oncogene 2014 33 2826 2835 23770846

Cited by

Sorted by citations

Authors
Duan, Y., Tian, L., Gao, Q., Liang, L., Zhang, W., Yang, Y., Zheng, Y., Pan, E., Li, S., & Tang, N.
Affiliations
Second Affiliated Hospital of Chongqing Medical University (CN)
Corresponding author
  • Duan, Yujie
  • Tian, Ling
  • Gao, Qingzhu
ORCID
Venue
Oncotarget
Publisher
Impact Journals, LLC
Published
2016-06-23
Volume
7
Issue
29
Pages
45863-45875
ISSN
1949-2553 (ISSN-L)
DOI
10.18632/oncotarget.10244
PMC
PMC5216766
OpenAlex
W2467932866
Cited by
50
References
2
Citations by year
2026: 3 · 2025: 4 · 2024: 9 · 2023: 3 · 2022: 7 · 2021: 4 · 2020: 8 · 2019: 3 · 2018: 3 · 2017: 6
FWCI
2.08
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Oncotarget (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Chongqing Medical University (201401)
  • Hong Kong Polytechnic University
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords
ARID2, SWI/SNF complex, hepatocellular carcinoma, cyclin D1, cyclin E1, Rb/E2F pathway, E2F1, cell cycle progression, G1/S transition, tumor suppressor, CCND1, cell proliferation
MeSH terms
Animals, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Mice, Nude, Transcription Factors, Oncogene Proteins, Disease Progression, Cyclin E, Cyclin D1, Chromatin Assembly and Disassembly, Cell Line, Tumor, Mice, Heterografts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review